Mari Kannagi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4039552/publications.pdf

Version: 2024-02-01

		201385	197535
54	2,468	27	49
papers	citations	h-index	g-index
- 4	- 4		10.40
56	56	56	1848
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. International Immunology, 1991, 3, 761-767.	1.8	250
2	Induction of Bcl-x _L Expression by Human T-Cell Leukemia Virus Type 1 Tax through NF-1ºB in Apoptosis-Resistant T-Cell Transfectants with Tax. Journal of Virology, 1999, 73, 7981-7987.	1.5	201
3	Cell surface phenotypes and expression of viral antigens of various human cell lines carrying human T-cell leukemia virus. International Journal of Cancer, 1984, 34, 221-228.	2.3	199
4	Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood, 2005, 105, 4143-4145.	0.6	151
5	Graft-versus-Tax Response in Adult T-Cell Leukemia Patients after Hematopoietic Stem Cell Transplantation. Cancer Research, 2004, 64, 391-399.	0.4	133
6	Augmentation of chemokine production by severe acute respiratory syndrome coronavirus 3a/X1 and 7a/X4 proteins through NF-κB activation. FEBS Letters, 2006, 580, 6807-6812.	1.3	111
7	Clinical outcomes of a novel therapeutic vaccine with Tax peptideâ€pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. British Journal of Haematology, 2015, 169, 356-367.	1.2	101
8	Prevention of Adult T-Cell Leukemia-Like Lymphoproliferative Disease in Rats by Adoptively Transferred T Cells from a Donor Immunized with Human T-Cell Leukemia Virus Type 1 Tax-Coding DNA Vaccine. Journal of Virology, 2000, 74, 9610-9616.	1,5	73
9	Interferon-α (IFN-α) suppresses HTLV-1 gene expression and cell cycling, while IFN-α combined with zidovudin induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology, 2013, 10, 52.	0.9	64
10	Expression of the target antigen for cytotoxic T lymphocytes on adult T-cell-leukemia cells. International Journal of Cancer, 1993, 54, 582-588.	2.3	63
11	Regression of Human T-cell Leukemia Virus Type I (HTLV-I)-Associated Lymphomas in a Rat Model: Peptide-Induced T-Cell Immunity. Journal of the National Cancer Institute, 2001, 93, 1775-1783.	3.0	63
12	Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning for Adult T Cell Leukemia/Lymphoma: Impact of Antithymocyte Globulin on Clinical Outcome. Biology of Blood and Marrow Transplantation, 2008, 14, 702-708.	2.0	56
13	Stromal Cell-Mediated Suppression of Human T-Cell Leukemia Virus Type 1 Expression In Vitro and In Vivo by Type I Interferon. Journal of Virology, 2009, 83, 5101-5108.	1.5	53
14	Expression of FAP-1 (Fas-Associated Phosphatase) and Resistance to Fas-Mediated Apoptosis in T Cell Lines Derived from Human T Cell Leukemia Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis Patients. AIDS Research and Human Retroviruses, 1998, 14, 261-267.	0.5	52
15	Expansion of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Reservoir in Orally Infected Rats: Inverse Correlation with HTLV-1-Specific Cellular Immune Response. Journal of Virology, 2003, 77, 2956-2963.	1.5	52
16	Immunological risks of adult T-cell leukemia at primary HTLV-I infection. Trends in Microbiology, 2004, 12, 346-352.	3.5	52
17	Fate of HIV-1 cDNA intermediates during reverse transcription is dictated by transcription initiation site of virus genomic RNA. Scientific Reports, 2016, 5, 17680.	1.6	46
18	Tumor immunity against adult T-cell leukemia. Cancer Science, 2005, 96, 249-255.	1.7	45

#	Article	IF	CITATIONS
19	Potential immunogenicity of adult T cell leukemia cellsin vivo. International Journal of Cancer, 2005, 114, 257-267.	2.3	45
20	Activation of Oncogenic Transcription Factor AP-1 in T Cells Infected with Human T Cell Leukemia Virus Type 1. AIDS Research and Human Retroviruses, 2000, 16, 1603-1606.	0.5	38
21	Induction of Adult T-Cell Leukemia-Like Lymphoproliferative Disease and Its Inhibition by Adoptive Immunotherapy in T-Cell-Deficient Nude Rats Inoculated with Syngeneic Human T-Cell Leukemia Virus Type 1-Immortalized Cells. Journal of Virology, 1999, 73, 6031-6040.	1.5	36
22	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathogens, 2017, 13, e1006597.	2.1	36
23	Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL. Retrovirology, 2019, 16, 23.	0.9	36
24	Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Archives of Virology, 2009, 154, 1457-1464.	0.9	33
25	Functional impairment of Tax-specific but not cytomegalovirus-specific CD8+ T lymphocytes in a minor population of asymptomatic human T-cell leukemia virus type 1-carriers. Retrovirology, 2011, 8, 100.	0.9	31
26	Oral Administration of Human T-Cell Leukemia Virus Type 1 Induces Immune Unresponsiveness with Persistent Infection in Adult Rats. Journal of Virology, 1998, 72, 7289-7293.	1.5	31
27	Human T-cell leukemia virus type 1 Tax protein induces the expression of STAT1 and STAT5 genes in T-cells. Oncogene, 1999, 18, 2667-2675.	2.6	30
28	Repression of Tax Expression Is Associated both with Resistance of Human T-Cell Leukemia Virus Type 1-Infected T Cells to Killing by Tax-Specific Cytotoxic T Lymphocytes and with Impaired Tumorigenicity in a Rat Model. Journal of Virology, 2004, 78, 3827-3836.	1.5	29
29	Development of Human T-Cell Leukemia Virus Type 1-Transformed Tumors in Rats following Suppression of T-Cell Immunity by CD80 and CD86 Blockade. Journal of Virology, 2000, 74, 428-435.	1.5	28
30	Immunologic Control of Human T-Cell Leukemia Virus Type I and Adult T-Cell Leukemia. International Journal of Hematology, 2007, 86, 113-117.	0.7	28
31	Immunological Aspects of Rat Models of HTLV Type 1-Infected T Lymphoproliferative Disease. AIDS Research and Human Retroviruses, 2000, 16, 1737-1740.	0.5	26
32	Maintenance of long remission in adult Tâ€cell leukemia by Taxâ€targeted vaccine: A hope for diseaseâ€preventive therapy. Cancer Science, 2019, 110, 849-857.	1.7	26
33	Identification of Two New HLA-A*1101-Restricted Tax Epitopes Recognized by Cytotoxic T Lymphocytes in an Adult T-Cell Leukemia Patient after Hematopoietic Stem Cell Transplantation. Journal of Virology, 2005, 79, 10088-10092.	1.5	25
34	The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases. Frontiers in Microbiology, 2012, 3, 323.	1.5	24
35	Establishment of a Seronegative Human T-Cell Leukemia Virus Type 1 (HTLV-1) Carrier State in Rats Inoculated with a Syngeneic HTLV-1-Immortalized T-Cell Line Preferentially Expressing Tax. Journal of Virology, 1999, 73, 6436-6443.	1.5	24
36	Impaired Taxâ€specific Tâ€cell responses with insufficient control of HTLVâ€1 in a subgroup of individuals at asymptomatic and smoldering stages. Cancer Science, 2009, 100, 481-489.	1.7	19

3

#	Article	IF	Citations
37	Suppression of human immunodeficiency virus type 1 replication by arginine deiminase of Mycoplasma arginini. Journal of General Virology, 2006, 87, 1589-1593.	1.3	18
38	Adult T-cell leukemia: future prophylaxis and immunotherapy. Expert Review of Anticancer Therapy, 2004, 4, 369-376.	1.1	17
39	Double control systems for human Tâ€cell leukemia virus type 1 by innate and acquired immunity. Cancer Science, 2011, 102, 670-676.	1.7	17
40	Critical Contribution of Tyr15 in the HIV-1 Integrase (IN) in Facilitating IN Assembly and Nonenzymatic Function through the IN Precursor Form with Reverse Transcriptase. Journal of Virology, 2017, 91, .	1.5	13
41	Reduction of Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Loads in Rats Orally Infected with HTLV-1 by Reimmunization with HTLV-1-Infected Cells. Journal of Virology, 2006, 80, 7375-7381.	1.5	12
42	A novel mother-to-child human T-cell leukaemia virus type 1 (HTLV-1) transmission model for investigating the role of maternal anti-HTLV-1 antibodies using orally infected mother rats. Journal of General Virology, 2017, 98, 835-846.	1.3	12
43	Potential Contribution of a Novel Tax Epitope–Specific CD4+T Cells to Graft-versus-Tax Effect in Adult T Cell Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Immunology, 2013, 190, 4382-4392.	0.4	11
44	ILâ€2 withdrawal induces HTLVâ€1 expression through p38 activation in ATL cell lines. FEBS Letters, 2007, 581, 5207-5212.	1.3	10
45	Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area. Intractable and Rare Diseases Research, 2015, 4, 181-189.	0.3	10
46	HTLV-1 Tax-Specific CTL Epitope–Pulsed Dendritic Cell Therapy Reduces Proviral Load in Infected Rats with Immune Tolerance against Tax. Journal of Immunology, 2017, 198, 1210-1219.	0.4	9
47	Inhibition of human immunodeficiency virus type 1 replication by Z-100, an immunomodulator extracted from human-type tubercle bacilli, in macrophages. Journal of General Virology, 2004, 85, 2603-2613.	1.3	8
48	Human T-cell leukemia virus type-I (HTLV-I)-specific T-cell responses detected using three-divided glutathione-S-transferase (GST)-Tax fusion proteins. Journal of Immunological Methods, 2006, 313, 61-73.	0.6	7
49	Shortâ€ŧerm cultured autologous peripheral blood mononuclear cells as a potential immunogen to activate Taxâ€specific CTL response in adult Tâ€cell leukemia patients. Cancer Science, 2021, 112, 1161-1172.	1.7	6
50	Impact of $5\hat{a}\in^2$ -end nucleotide modifications of HIV-1 genomic RNA on reverse transcription. Biochemical and Biophysical Research Communications, 2019, 516, 1145-1151.	1.0	4
51	Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells. Biochemical and Biophysical Research Communications, 2021, 574, 104-109.	1.0	4
52	Durable Remission with Decreased HTLV-I Proviral Load after Reduced-Intensity Stem Cell Transplantation (RIST) in Patients with Adult T-Cell Leukemia/Lymphoma (ATL) Blood, 2005, 106, 3347-3347.	0.6	0
53	A Therapeutic Vaccine In Adult T-Cell Leukemia Patients With Autologous Dendritic Cells Pulsed With Peptides Corresponding To Tax-Specific Cytotoxic T Lymphocyte Epitopes. Blood, 2013, 122, 5130-5130.	0.6	O
54	Tax-Targeting Dendritic Cell Therapy for ATL: A Phase Ia/Ib Clinical Study. Blood, 2018, 132, 1649-1649.	0.6	0